{"url_path":"/sec/prme/8-k/2026-07-08/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1894562/0001628280-26-047590-index.html","accession_number":"0001628280-26-047590","cik":"0001894562","ticker":"PRME","issuer_name":"Prime Medicine, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1894562/0001628280-26-047590-index.html","primary_entity_key":"0001894562","primary_entity_name":"Prime Medicine, Inc."},"word_count":170,"has_tables":true,"body_markdown":"Item 8.01 Other Events\n\nOn July 6, 2026, Prime Medicine, Inc. (the \"Company\") received a final award (the \"Final Award\") from the arbitration tribunal (the \"Tribunal\") in the Company's binding arbitration proceedings with Beam Therapeutics, Inc. (\"Beam\") regarding the parties' 2019 Collaboration and License Agreement (the \"Agreement\"). In the Final Award, the Tribunal declared that PM647, the Company's development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (\"AATD\"), is within the Company's \"Field\" as defined by the Agreement, and that the Company therefore did not breach the Agreement. Consequently, the Tribunal denied Beam's requests for damages and injunctive relief based on Beam's assertion that Prime breached the Agreement. The Tribunal denied the remaining claims brought by Beam and the Company.\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: July 8, 2026\n\nPrime Medicine, Inc.\n\nBy:\n\n/s/ Allan Reine\n\nName:\n\nAllan Reine, M.D.\n\nTitle:\n\nChief Executive Officer"}